InVivoSIM anti-human VEGFR-2 (Ramucirumab Biosimilar)
Catalog #SIM0012
Clone:
Ramucirumab
Reactivities:
Human
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Ramucirumab making it ideal for research use. This Ramucirumab biosimilar reacts with human VEGFR-2 (vascular endothelial growth factor receptor 2) also known as CD309, KDR, and Flk-1. VEGFR-2 is a member of the tyrosine protein kinase family. Upon binding to its ligand VEGF, VEGFR-2 pays key roles in vascular development and permeability. VEGFR-2 is expressed on endothelial cells at high levels in adult heart, lung, kidney, brain, and skeletal muscle as well as other tissues at lower levels. Ramucirumab binds to the extracellular domain of VEGFR-2 and blocks the binding of VEGFR ligands VEGF-A, VEGF-C and VEGF-D leading to inhibition of VEGF-mediated tumor angiogenesis.Specifications
Isotype | Human IgG1 |
---|---|
Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
Immunogen | Human VEGFR2 |
Reported Applications |
Functional assays Immunohistochemistry Flow cytometry |
Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
Endotoxin |
<1EU/mg (<0.001EU/Ī¼g) Determined by LAL gel clotting assay |
Sterility | 0.2 Āµm filtration |
Production | Purified from cell culture supernatant |
Purification | Protein A |
RRID | AB_2894733 |
Molecular Weight | 150 kDa |
Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |